Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors
December 18, 2018 16:05 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Carol A. Schafer joined its Board of Directors, effective December 18, 2018. Ms....
Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
December 14, 2018 07:00 ET
|
Idera Pharmaceuticals, Inc.
- 32.4% of patients evaluable for efficacy achieved partial response or better; 76.5% of patients achieved disease control - - Tumor shrinkage observed in both injected and uninjected lesions,...
Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018
December 12, 2018 16:01 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug...
Idera Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 06, 2018 16:30 ET
|
Idera Pharmaceuticals, Inc.
– Company to Provide ILLUMINATE 204 Data Update in the First Half of December 2018 –– Cash runway into first quarter of 2020 – EXTON, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals,...
Idera Pharmaceuticals Presents Data from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment at the 2018 European Society for Medical Oncology (ESMO) Congress
October 19, 2018 06:00 ET
|
Idera Pharmaceuticals, Inc.
- Key findings presented in poster discussion demonstrate clear abscopal effect of intratumoral tilsotolimod - - Data demonstrate contribution of tilsotolimod to overcome resistance to ipilimumab in...
Idera Pharmaceuticals Announces Appointment of Howard Pien to its Board of Directors
September 18, 2018 16:01 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...
Idera Pharmaceuticals Announces Corporate Organizational Changes
September 11, 2018 07:00 ET
|
Idera Pharmaceuticals, Inc.
- Bryant D. Lim appointed as General Counsel and Secretary of the Board of Directors - - Chief Financial Officer Louis J. Arcudi III departing the company related to company consolidation to...
Idera Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
August 30, 2018 07:30 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...
Idera Pharmaceuticals To Present at the 2018 Wedbush PacGrow Healthcare Conference
August 09, 2018 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...
Idera Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 02, 2018 16:30 ET
|
Idera Pharmaceuticals, Inc.
Abstract accepted for 2018 European Society of Medical Oncology Annual Meeting Cash runway into first quarter of 2020 EXTON, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc....